Pharmaceutical composition for treating cancer as well as preparation method and application thereof
The drug composition, consisting of ester compounds and dimethyl sulfoxide, targets tumor cells, solving the problems of high toxicity and poor efficacy of existing chemotherapy drugs. It achieves effective treatment of malignant tumors with low toxicity, and inhibits tumor growth and metastasis.
Patent Information
- Application Number
- CN202410871062.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-12-31
- Filing Date
- 2021-12-31
- Publication Date
- 2024-11-15
AI Technical Summary
Existing chemotherapy drugs have limited effectiveness in treating cancer and are highly toxic. Targeted therapy and immunotherapy also face drug resistance problems. There is an urgent need for a drug with fewer side effects and better stability to treat malignant tumors.
A drug composition consisting of ester compounds (such as ethyl acetate), dimethyl sulfoxide, and lactic acid is used to inhibit tumor cell proliferation and invasion by altering the environment surrounding tumor cells. It targets aldehyde compounds on the cell membrane, avoiding damage to normal tissue cells.
This drug composition has a significant effect on malignant tumor cells, low toxicity, no side effects, can inhibit tumor growth and metastasis, enhance cell membrane permeability, improve the patient's physical condition, and does not damage normal tissue cells.
Smart Images

Figure BDA0004921650450000091 
Figure BDA0004921650450000101 
Figure HDA0004921650460000011
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a pharmaceutical composition for treating cancer, a preparation method thereof and use thereof. Background Art
[0002] The global medical community is almost helpless in the treatment of cancer, i.e. malignant tumors. Traditional treatment methods mainly include surgery, radiotherapy, and chemotherapy. Only a very small number of patients can be cured by surgical resection in the early stage of the disease. Radiotherapy has a weak effect, and existing chemotherapy drugs have limited effects and can only maintain or prolong life for a short time. The chemotherapy drugs currently used in clinical practice are highly toxic and ineffective, and cannot effectively cure malignant tumors. Targeted therapy and immunotherapy began to emerge in the late 1990s. Although they have certain therapeutic effects, the emergence of drug-resistant genes is currently the main obstacle to further improving the efficacy.
[0003] Therefore, there is an urgent need for a drug with significant effects, few toxic side effects and good stability to treat malignant tumors. Summary of the invention
[0004] In order to solve the problems existing in the prior art, the present invention provides a pharmaceutical composition for treating or preventing cancer, and a preparation method and use thereof. The pharmaceutical composition is composed of dimethyl sulfoxide and an ester compound, and the pharmaceutical composition of the present invention has great value for the prevention and treatment of cancer.
[0005] The present invention is achieved through the following technical solutions.
[0006] In one aspect, the present invention provides a pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition comprising an ester compound and dimethyl sulfoxide.
[0007] Preferably, the ester compound is C 2-8 A lower ester, preferably C 2-4 A lower ester of, more preferably ethyl acetate;
[0008] Preferably, the pharmaceutical composition consists of ethyl acetate and dimethyl sulfoxide.
[0009] Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:1-1:200;
[0010] Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:100-1:200.
[0011] Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:75-1:150.
[0012] Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:100.
[0013] Preferably, the ethyl acetate and the dimethyl sulfoxide are administered alone or in combination, diluted with water, and directly taken orally, injected, or sprayed as a method of treating or preventing animal and human diseases.
[0014] Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
[0015] The present invention also provides another pharmaceutical composition for treating or preventing cancer, which is composed of a ketone compound and dimethyl sulfoxide.
[0016] Preferably, the ketone compound is an alkanone, preferably C 3-6 An alkanone, more preferably acetone;
[0017] Preferably, the pharmaceutical composition consists of acetone and dimethyl sulfoxide.
[0018] Preferably, the volume ratio between the acetone and the dimethyl sulfoxide is 1:1-1:200;
[0019] Preferably, the volume ratio between the acetone and the dimethyl sulfoxide is 1:100-1:200;
[0020] Preferably, the volume ratio between the acetone and the dimethyl sulfoxide is 1:75-1:150;
[0021] Preferably, the acetone and the dimethyl sulfoxide are administered alone or in combination, diluted with water, and directly taken orally, injected, or sprayed as a method of treating or preventing animal and human diseases.
[0022] Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
[0023] In addition, the present invention also provides another pharmaceutical composition for treating or preventing cancer, which is composed of an alcohol compound and dimethyl sulfoxide.
[0024] Preferably, the alcohol compound is C 1-6 The alkanol, preferably C 1-4 An alkanol, more preferably ethanol;
[0025] Preferably, the pharmaceutical composition consists of ethanol and dimethyl sulfoxide.
[0026] Preferably, the volume ratio between the ethanol and the dimethyl sulfoxide is 1:1-1:200;
[0027] Preferably, the volume ratio between the ethanol and the dimethyl sulfoxide is 1:100-1:200;
[0028] Preferably, the volume ratio of the ethanol to the dimethyl sulfoxide is 1:75-1:150; preferably, the ethanol and the dimethyl sulfoxide are administered alone or as a mixture, diluted with water and directly taken orally, injected, or sprayed as a method of administration for treating or preventing animal and human diseases.
[0029] Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
[0030] On the other hand, the present invention provides the use of the above-mentioned pharmaceutical composition in the preparation of drugs for preventing and / or treating various diseases such as cancer, cancer complications, cerebral edema, diabetes, hypertension, cardiovascular and cerebrovascular diseases, lupus erythematosus, pleural effusion, ascites and gout.
[0031] Preferably, the administration routes of the pharmaceutical composition include, but are not limited to, oral administration, intravenous drip, intravenous injection, transdermal administration and other administration routes.
[0032] Preferably, the cancer includes, but is not limited to, glioma, astrocytoma, brain or central nervous system cancer, peripheral nervous system cancer, such as melanoma, B cell cancer, multiple myeloma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, bile duct cancer, small intestine cancer or appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, blood tissue cancer, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphatic endothelial Sarcoma, synovial tumor, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, idiopathic myeloid metaplasia, hypereosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, carcinoid tumor, and their metastatic and invasive lesions. The pharmaceutical composition of the present application is also suitable for the treatment of diabetes, cardiovascular and cerebrovascular diseases, lupus erythematosus, pleural effusion, ascites and gout.
[0033] The target of the pharmaceutical composition of the present invention is aldehyde compounds attached to the cell membrane. Aldehyde compounds or aldehyde proteins attached to the cell membrane are anchored by reacting alcohols, esters, ketones, acids and the like with aldehyde compounds. At the same time, the proliferation, infiltration or aggregation of tumor cells are inhibited by changing the environment surrounding tumor cells, thereby curbing tumor growth.
[0034] The pharmaceutical composition of the present invention is a broad-spectrum anticancer drug. In clinical practice, physicians with rich experience should give different dosage ratios of drugs alone, alternately or in combination according to different stages of the patient's condition and different symptoms, so that the therapeutic effect will be better.
[0035] Compared with the prior art, the pharmaceutical composition of the present application has the following advantages:
[0036] (1) The present invention directly mixes the solvents, which is simple and easy to operate. However, in animal experiments, adding 4.55% lactic acid to each composition in proportion will show a better effect on tumor control. It is suitable for the treatment of various cancers.
[0037] (2) The pharmaceutical composition of the present invention is a precise tumor inhibitor that has a pharmacological effect only on malignant tumor cells without damaging normal tissue cells. It can avoid killing and inhibiting normal tissue cells and only inhibit the proliferation of malignant tumor cells and infiltration of normal tissue cells.
[0038] (3) The solvent used in the pharmaceutical composition of the present invention has clear physical and chemical indicators and is easy to control. Its pharmacokinetic and toxicity are easy for professionals and patients to clearly judge.
[0039] (4) Compared with cancer treatment drugs that have been marketed at home and abroad, the pharmaceutical composition of the present invention has low toxicity, which can even be ignored, and has no side effects. Accurate and normal dosage administration will not cause any harm to the human body.
[0040] (5) The pharmaceutical composition of the present invention is different from existing anti-tumor drugs. While inhibiting the growth of solid tumors, it can also effectively inhibit the secondary growth of tumor cells and nodules in other tissues (so-called tumor metastasis).
[0041] (6) The pharmaceutical composition of the present invention can effectively reduce transmembrane impedance, enhance cell membrane permeability, enable the body's tissue cells to timely and effectively utilize glucose, salt, water, etc., and enhance the patient's physical fitness.
[0042] (7) The pharmaceutical composition of the present invention suppresses the massive proliferation of tumor cells and prevents the tumor cells from infiltrating normal tissue cells by denaturing the outer membrane proteins of tumor cells and affecting the environment. When the drug causes the tumor cells to proliferate slower than normal tissue cells and stops infiltrating normal tissue cells, the tumor volume gradually shrinks or remains unchanged.
[0043] It should be understood that the invention described herein is not limited to specific methodology, experimental protocols or reagents, as these may vary. The discussion and examples provided herein are presented only to describe specific embodiments and are not intended to limit the scope of the invention, which is limited only by the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0044] Figure 1 : Tumor inhibition rate of the pharmaceutical composition of the present invention;
[0045] Figure 2 : Tumor anatomy atlas, which shows the experimental results of solvent control group, 5-fluorouracil group, temozolomide group, high, medium and low dose groups from top to bottom;
[0046] Figure 3 : Trend of tumor volume changes during drug administration;
[0047] Figure 4 : Trend of body weight changes during medication. DETAILED DESCRIPTION
[0048] The experimental materials and sources in the following examples are as follows:
[0049] Dimethyl sulfoxide: (≥99.5%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20181010;
[0050] Ethanol: (≥95.0%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20200810;
[0051] Acetone: (≥99.5%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20140221;
[0052] Ethyl acetate: (≥99.5%), Sinopharm Chemical Reagent Co., Ltd., batch number: 20161026;
[0053] Example 1 Pharmaceutical composition of the present invention
[0054] Formula: 200 mL of dimethyl sulfoxide, 1 mL of ethyl acetate;
[0055] Formula: dimethyl sulfoxide 180mL, ethyl acetate 1mL;
[0056] Formula: dimethyl sulfoxide 160mL, ethyl acetate 1mL;
[0057] Formula: dimethyl sulfoxide 140mL, ethyl acetate 1mL;
[0058] Formula: dimethyl sulfoxide 120mL, ethyl acetate 1mL;
[0059] Formula: dimethyl sulfoxide 100mL, ethyl acetate 1mL;
[0060] Formula: 80 mL of dimethyl sulfoxide, 1 mL of ethyl acetate;
[0061] Formula: 60 mL of dimethyl sulfoxide, 1 mL of ethyl acetate;
[0062] Formula: dimethyl sulfoxide 40mL, ethyl acetate 1mL;
[0063] Formula: dimethyl sulfoxide 20mL, ethyl acetate 1mL;
[0064] Formula: dimethyl sulfoxide 1mL, ethyl acetate 1mL.
[0065] Example 2 Pharmaceutical composition of the present invention
[0066] Formula: 200 mL of dimethyl sulfoxide, 1 mL of acetone;
[0067] Formula: 180 mL of dimethyl sulfoxide, 1 mL of acetone;
[0068] Formula: dimethyl sulfoxide 160mL, acetone 1mL;
[0069] Formula: dimethyl sulfoxide 140mL, acetone 1mL;
[0070] Formula: dimethyl sulfoxide 120mL, acetone 1mL;
[0071] Formula: dimethyl sulfoxide 100mL, acetone 1mL;
[0072] Formula: 80 mL of dimethyl sulfoxide, 1 mL of acetone;
[0073] Formula: 60 mL of dimethyl sulfoxide, 1 mL of acetone;
[0074] Formula: 40 mL of dimethyl sulfoxide, 1 mL of acetone;
[0075] Formula: 20 mL of dimethyl sulfoxide, 1 mL of acetone;
[0076] Formula: 1 mL of dimethyl sulfoxide and 1 mL of acetone.
[0077] Example 3 Pharmaceutical composition of the present invention
[0078] Formula: 200 mL of dimethyl sulfoxide, 1 mL of ethanol;
[0079] Formula: dimethyl sulfoxide 180mL, ethanol 1mL;
[0080] Formula: dimethyl sulfoxide 160mL, ethanol 1mL;
[0081] Formula: dimethyl sulfoxide 140mL, ethanol 1mL;
[0082] Formula: dimethyl sulfoxide 120mL, ethanol 1mL;
[0083] Formula: dimethyl sulfoxide 100mL, ethanol 1mL;
[0084] Formula: 80 mL of dimethyl sulfoxide, 1 mL of ethanol;
[0085] Formula: 60 mL of dimethyl sulfoxide, 1 mL of ethanol;
[0086] Formula: 40 mL of dimethyl sulfoxide, 1 mL of ethanol;
[0087] Formula: dimethyl sulfoxide 20mL, ethanol 1mL;
[0088] Formula: 1 mL of dimethyl sulfoxide and 1 mL of ethanol.
[0089] Example 4 Effect of the pharmaceutical composition of the present invention on treating cancer
[0090] 1. Main instruments and equipment
[0091] Commonly used laboratory instruments include dissecting instruments, biological microscopes, animal weighing scales, analytical balances, water baths, pipettes, vortex mixers, biological safety cabinets, cell culture incubators, etc.
[0092] 2. Reagents
[0093] Disinfectant, saline solution for injection, medical alcohol, etc.
[0094] 3. Positive drugs
[0095] 3.1 Positive Control 1
[0096] Name: Fluorouracil Injection
[0097] Manufacturer: Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
[0098] Batch number: FA181206
[0099] Packaging: Glass ampoule
[0100] Specification: 10mL: 0.25g
[0101] Appearance: Colorless clear liquid
[0102] Storage conditions: Store at 15-25℃ away from light, do not freeze
[0103] Valid until December 12, 2020
[0104] 3.2 Positive Control 2
[0105] Name: Temozolomide for injection
[0106] Manufacturer: Jiangsu Hengrui Medicine Co., Ltd.
[0107] Batch number: 190711AM
[0108] Packaging: Vial
[0109] Specification: 100mg / piece
[0110] Appearance: White freeze-dried block
[0111] Storage conditions: airtight storage (2~8℃)
[0112] Valid until July 10, 2021
[0113] 4. Experimental Animals
[0114] Animal strain: BALB / C-nu / nu mice
[0115] Animal grade: SPF grade
[0116] Sex and number: Female, 42;
[0117] Animal age at the start of the experiment: 6 weeks old
[0118] Animal weight at the start of the experiment: 18 ± 2 g;
[0119] Source of animals: Weitong Lihua Laboratory Animal Technology Co., Ltd.
[0120] 5. Quarantine
[0121] The experimental animals were inspected and quarantined according to the test requirements. The adaptability was observed for 5 days, during which the eyes, ears, nose, oral cavity, fur, abdomen, vulva, perianal area, limbs, claws, toes, gait, behavior, excretion, food intake, and drinking water were observed and recorded. The experiment was conducted on mice with normal quarantine.
[0122] 6. Grouping
[0123] In the experiment, mice that passed the quarantine were selected, randomly divided into groups after tumor inoculation, and marked and raised separately in cages.
[0124] 7. Rearing conditions
[0125] Qingdao Marine Biomedicine Research Institute Co., Ltd. Laboratory Animal Use License Number:
[0126] SYXK(Lu)2015 0011
[0127] The laboratory temperature is 20-25℃, the humidity is 40-70%, the ventilation frequency is 10-20 times / hour, the light is 12 hours of light and dark alternation, and the stocking density is less than 5 per cage. The breeding environment is strictly in accordance with the relevant standards of the National Standard of the People's Republic of China - Laboratory Animals.
[0128] 8. Tumor cell line information
[0129] Cell source and culture conditions: U-87MG human astrocytic glioblastoma cells were obtained from the Cell Resource Center of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. The culture medium used was MEM medium containing 1% penicillin-streptomycin sulfate double antibody mixture (100×) and 10% fetal bovine serum (from Australia). The culture conditions were 5% CO 2 , 37℃, and stored in our center.
[0130] 9. Cell recovery and passaging
[0131] U-87MG cell lines were resuscitated in liquid nitrogen and placed in the corresponding culture medium containing 10% FBS (fetal bovine serum), 100 U / ml penicillin and 100 μg / ml streptomycin at 37°C and 5% CO 2 The cells were cultured in a cell culture incubator and passaged every two days.
[0132] 10. Tumor inoculation
[0133] After four passages, the cells were collected by digestion with 0.05% trypsin-EDTA, the number of cells was counted under a microscope, and the cells were resuspended in culture medium to 5 × 10 7 Cell suspension of 100 cells / ml was routinely disinfected and inoculated into the subcutaneous part of the axilla of the right forelimb of mice at 0.2 ml per cell. The suspension was removed aseptically, weighed, diluted and ground with sodium chloride injection at a mass-to-volume ratio of 1:4, and routinely disinfected and inoculated into the subcutaneous part of the axilla of the right forelimb of mice at 0.2 ml per cell for passage. The mice were kept normally during this period, and the status of the mice and the tumor conditions were observed and recorded weekly.
[0134] The tumor volume of the tumor-bearing mice to be passaged is 1200mm 3 The same method was used to grind and transplant the tumors for modeling. After tumor inoculation, the mice were weighed and randomly selected to form 6 groups of 7 mice each. Drug administration began after tumor implantation, which was recorded as day 1 (D1).
[0135] 11. Animal grouping and dosing
[0136] The animals were randomly divided into 6 groups according to their body weight, with 7 animals in each group. The dosage of each group of animals is as follows:
[0137] Table 1 Grouping and drug administration
[0138]
[0139] 12. Clinical Observation
[0140] 12.1 General clinical observations
[0141] Animals to observe: All animals
[0142] Observation frequency and time: Observe once before each drug administration during the experiment, and record the drug administration and observation.
[0143] Observation content: including but not limited to tumor growth, animal mental state, diet, etc.
[0144] 12.2 Weight
[0145] Test animals: All animals
[0146] Testing time: weigh the animals and record the weights before grouping (i.e., before the first administration) (D1), each subsequent administration, and before euthanasia.
[0147] Weighing records of animals that died unexpectedly, and other related records.
[0148] 12.3 Evaluation of therapeutic efficacy based on tumor weight
[0149] At the end of the experiment, the tumor tissues of the animals that died unexpectedly and the animals that survived were euthanized and the tumor weights were weighed. The differences in tumor weights of the groups were calculated to further calculate the tumor inhibition rate IRTW. The calculation formula is as follows:
[0150] IRTW (%) = (W model group - W drug administration group) / W model group × 100%
[0151] 13. Photographic Records
[0152] After the animals were euthanized, the tumor tissues were removed and photographed.
[0153] 14. Data collection and statistical analysis
[0154] The protocol requires that the measured and observed data results be recorded by hand on an appropriate form or collected directly by computer. The data are used as raw data for analysis, processing and reporting. The results are expressed as mean and standard deviation (Mean±SD). The t-test is used for comparison between the two groups, and both statistical significance and biological significance are considered when analyzing the results.
[0155] 15. Results
[0156] 15.1 General clinical observations
[0157] When the high-dose group was given the drug twice a day with a total dose of 13.5 ml / kg, two mice in the high-dose group died on the third day, and the remaining mice were curled up, with no mucus flowing out of the corners of the mouth and nose, eyes closed, and body surface temperature felt low. They were inactive and did not eat. Subsequently, the high-dose group reduced the dose to 6.75 ml / kg until the end of the experiment, and no deaths occurred. The mice in the remaining groups were in good condition.
[0158] 15.2 Tumor inhibition rate statistics
[0159] The statistical results of tumor inhibition rate are shown in Figure 1 and Table 2.
[0160] Table 2
[0161]
[0162] Figure 2 This is a tumor anatomical atlas, from top to bottom: solvent control group, 5-fluorouracil group, temozolomide group, high, medium and low dose groups. Figure 3Figure 2 is the trend of tumor volume changes during drug administration. Figure 4 This is the trend of body weight changes during the medication period.
[0163] It can be seen from the experimental data that after adjusting the dosage, the tumor volume began to show obvious differences on the 7th day of administration. From 11 to 15 days of administration, the tumor inhibition rates of the high, medium and low dose groups were dose-dependent. The final autopsy showed that the tumor inhibition rate of the high dose group was 46.4%. During the medication period, except for the 5-fluorouracil group which showed a decrease in weight in the later period of administration, the weight of the mice showed normal growth, indicating that after the mice adapted to the drug, there was no obvious impact on activities such as eating and digestion.
Claims
1. A pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition consisting of an ester compound and dimethyl sulfoxide; Preferably, the ester compound is C 2-8 A lower ester, preferably C 2-4 A lower ester of, more preferably ethyl acetate; Preferably, the pharmaceutical composition consists of ethyl acetate and dimethyl sulfoxide.
2. The pharmaceutical composition according to claim 1, in, The volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:1-1:200; Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:100-1:200; Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:75-1:150; Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:75-1:150; Preferably, the volume ratio between the ethyl acetate and the dimethyl sulfoxide is 1:100; Preferably, the ethyl acetate and the dimethyl sulfoxide are administered alone or in combination, diluted with water and directly orally, injected, sprayed, etc. as a method of administration for treating or preventing animal and human diseases; Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
3. A pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition consisting of a ketone compound and dimethyl sulfoxide; Preferably, the ketone compound is an alkanone, preferably C 3-6 An alkanone, more preferably acetone; Preferably, the pharmaceutical composition consists of acetone and dimethyl sulfoxide.
4. The pharmaceutical composition according to claim 3, in, The volume ratio between the acetone and the dimethyl sulfoxide is 1:1-1:200; Preferably, the volume ratio between the acetone and the dimethyl sulfoxide is 1:100-1:200; Preferably, the volume ratio between the acetone and the dimethyl sulfoxide is 1:75-1:150; Preferably, the acetone and the dimethyl sulfoxide are administered alone or in combination, diluted with water and directly orally, injected, or sprayed as a method of administration for treating or preventing animal and human diseases; Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
5. A pharmaceutical composition for treating or preventing cancer, the pharmaceutical composition consisting of an alcohol compound and dimethyl sulfoxide; Preferably, the alcohol compound is C 1-6 The alkanol, preferably C 1-4 An alkanol, more preferably ethanol; Preferably, the pharmaceutical composition consists of ethanol and dimethyl sulfoxide.
6. The pharmaceutical composition according to claim 5, in, The volume ratio between the ethanol and the dimethyl sulfoxide is 1:1-1:200; Preferably, the volume ratio between the ethanol and the dimethyl sulfoxide is 1:100-1:200; Preferably, the volume ratio between the ethanol and the dimethyl sulfoxide is 1:75-1:150; Preferably, the ethanol and the dimethyl sulfoxide are administered alone or in combination, diluted with water and directly orally, injected, sprayed, etc. as a method of administration for treating or preventing animal and human diseases; Preferably, the pharmaceutical composition further comprises 4.55 v / v% lactic acid.
7. Use of the pharmaceutical composition according to any one of claims 1 to 6 in the preparation of medicaments for preventing and / or treating various diseases such as cancer, cancer complications, cerebral edema, diabetes, hypertension, cardiovascular and cerebrovascular diseases, lupus erythematosus, pleural effusion, ascites and gout.
8. The use according to claim 7, It is characterized in that The administration routes of the pharmaceutical composition include, but are not limited to, oral administration, intravenous drip, intravenous injection, transdermal administration and other administration routes.
9. The use according to claim 7 or 8, It is characterized in that The cancers include, but are not limited to, gliomas, astrocytomas, brain or central nervous system cancers, peripheral nervous system cancers, such as melanoma, B-cell cancers, multiple myeloma, breast cancer, lung cancer, bronchial cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, bladder cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, oral cancer, pharyngeal cancer, liver cancer, kidney cancer, testicular cancer, bile duct cancer, small intestine cancer or appendix cancer, salivary gland cancer, thyroid cancer, adrenal cancer, osteosarcoma, chondrosarcoma, blood tissue cancer, adenocarcinoma, inflammatory myofibroblastic tumor, gastrointestinal stromal tumor (GIST), colon cancer, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), soft tissue sarcoma, fibrosarcoma, myxosarcoma, liposarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma , synovial tumor, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatocarcinoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, bladder cancer, epithelial carcinoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, neuroblastoma, retinoblastoma, follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, hepatocellular carcinoma, thyroid cancer, gastric cancer, head and neck cancer, small cell carcinoma, idiopathic myeloid metaplasia, eosinophilia, chronic eosinophilic leukemia, neuroendocrine carcinoma, carcinoid tumor, and their metastatic and invasive lesions.
10. The use according to claim 7 or 8, It is characterized in that The drug composition targets aldehyde compounds attached to cell membranes, and uses alcohols, esters, ketones, acids and other compounds to react with aldehyde compounds to anchor aldehyde compounds or aldehyde proteins attached to cell membranes. At the same time, it inhibits tumor cell proliferation and infiltration or aggregation by changing the environment around tumor cells, thereby curbing tumor growth.
